PuSH - Publikationsserver des Helmholtz Zentrums München

Puetz, A.* ; Artati, A. ; Adamski, J. ; Schuett, K.* ; Romeo, F.* ; Stoehr, R.* ; Marx, N.* ; Federici, M.* ; Lehrke, M.* ; Kappel, B.A.*

Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function.

ESC Heart Fail., DOI: 10.1002/ehf2.13713 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Aims: Chronic heart failure with reduced ejection fraction remains a major health issue. To date, no reliable biomarker is available to predict reduced left ventricular ejection fraction (LV-EF). We aimed to identify novel circulating biomarkers for reduced left ventricular function using untargeted serum metabolomics in two independent patient cohorts. Methods and results: Echocardiography and non-targeted serum metabolomics were conducted in two patient cohorts with varying left ventricular function: (1) 25 patients with type 2 diabetes with established cardiovascular disease or high cardiovascular risk (LV-EF range 20–66%) (discovery cohort) and (2) 37 patients hospitalized for myocardial infarction (LV-EF range 25–60%) (validation cohort). In the discovery cohort, untargeted metabolomics revealed seven metabolites performing better than N-terminal pro-B-type natriuretic peptide in the prediction of impaired left ventricular function shown by LV-EF. For only one of the metabolites, acisoga, the predictive value for LV-EF could be confirmed in the validation cohort (r = −0.37, P = 0.02). In the discovery cohort, acisoga did not only correlate with LV-EF (r = −60, P = 0.0016), but also with global circumferential strain (r = 0.67, P = 0.0003) and global longitudinal strain (r = 0.68, P = 0.0002). Similar results could be detected in the discovery cohort in a 6 month follow-up proofing stability of these results over time. With an area under the curve of 0.86 in the receiver operating characteristic analysis, acisoga discriminated between patients with normal EF and LV-EF < 40%. Multivariate analysis exposed acisoga as independent marker for impairment of LV-EF (Beta = −0.71, P = 0.004). Conclusions: We found the polyamine metabolite acisoga to be elevated in patients with impaired LV-EF in two independent cohorts. Our analyses suggest that acisoga may be a valuable biomarker to detect patients with heart failure with reduced ejection fraction.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Biomarker ; Ejection Fraction ; Heart Failure ; Hfref ; Metabolomics ; Polyamine Metabolism; Heart-failure; Spermidine
ISSN (print) / ISBN 2055-5822
e-ISSN 2055-5822
Zeitschrift ESC heart failure
Verlag Wiley
Verlagsort One Montgomery St, Suite 1200, San Francisco, Ca 94104 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
Institute of Experimental Genetics (IEG)
Förderungen Medizinische Fakultät, RWTH Aachen University
Deutsche Stiftung für Herzforschung
Fondazione Roma:
EU-FP7:
Corona Foundation
Deutsche Forschungsgemeinschaft
Ministry of University (MIUR)

Interreg